Paul J. Maddon
- Columbia, B.A., 1981
- Columbia, M.D., 1988
- Columbia, Ph.D., 1988
Dr. Maddon is a biotechnology entrepreneur and private investor who founded Progenics Pharmaceuticals, Inc., a biopharmaceutical company that develops and commercializes new medicines in the areas of gastroenterology, oncology, and infectious diseases. He founded Progenics in 1986 while an M.D.-Ph.D. student at Columbia University and has served as chairman, vice chairman, chief executive officer, and chief science officer until retiring in June 2016. Dr. Maddon led the development of the company’s commercial product, RELISTOR®, the first prescription drug in the world approved to treat opioid-induced constipation, a debilitating condition associated with opioid pain medication. RELISTOR® subcutaneous injection was launched in 2008 in the United States and Europe and is currently marketed worldwide. In July 2016, RELISTOR® tablets received marketing approval from the U.S. Food and Drug Administration. Dr. Maddon now serves as a director and senior advisor to several biotechnology and specialty pharmaceutical companies.
Dr. Maddon is a molecular virologist and immunologist who has made seminal contributions to our understanding of viral entry and infection. In a series of landmark studies as a graduate student in the laboratory of Dr. Richard Axel (University Professor at Columbia and Nobel laureate in Physiology or Medicine in 2004), he isolated the gene encoding CD4 and demonstrated that CD4 serves as the primary receptor for entry of the human immunodeficiency virus (HIV) into immune system cells. While at Progenics, Dr. Maddon discovered that a co-receptor, CCR5, is also required for HIV entry. The company’s PRO 140, a monoclonal antibody to CCR5 designed to treat HIV infection, is now being tested in phase 3 clinical trials.
Dr. Maddon has authored more than 50 peer-reviewed publications. He has served on the editorial board of Journal of Virology, and chaired and served on numerous scientific advisory committees of the National Institutes of Health and Department of Defense. Dr. Maddon has also received several honors, including Columbia’s Alumni Medal for Distinguished Service, John Jay Award, Dr. Alfred Steiner Award for Biomedical Research, Dr. Harold Lamport Biomedical Research Prize, and Lifetime of Learning Award, and has been awarded many federal research grants and contracts.
Dr. Maddon has a long-standing commitment to science education and to providing research opportunities for high school and college students. Together with high school science teachers in Westchester County, he founded the Westchester Science and Engineering Fair. Dr. Maddon serves as chairman of Columbia College’s Science Advisory Committee and The Rockefeller University’s Science Outreach Program, and is a member of the advisory committee of Columbia’s Science Honors Program. He serves as a trustee of the Society for Science & the Public, the Sabin Vaccine Institute, and NYSCI (New York Hall of Science). Dr. Maddon is a member of the Scientific Advisory Board of the Tri-Institutional (The Rockefeller University, Memorial Sloan-Kettering Cancer Center, and Weil Cornell Medical College) Therapeutics Discovery Institute, and was appointed by the Commissioner of Health for NYC in 2012 to serve as a director of the Fund for Public Health in New York. He is also a director of the Columbia Alumni Association and a member of the Board of Advisors of Columbia University Medical Center.
At Columbia, Dr. Maddon was graduated summa cum laude from the College with a B.A. in biochemistry and was elected to Phi Beta Kappa. He received an M.D. from the College of Physicians and Surgeons and a Ph.D. in biochemistry and molecular biophysics from the Graduate School of Arts and Sciences. Dr. Maddon was elected to serve as a Senate-consulted Trustee of Columbia University in 2008. He resides with his children in Scarsdale, New York.